Literature DB >> 16048969

In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

Clara Yustes1, Josep Guarro.   

Abstract

The in vitro interaction between amphotericin B and micafungin against 36 isolates of Scedosporium spp. has been evaluated using checkerboard assays and the minimal effective concentration endpoint. Synergy was found for 82.4% of Scedosporium prolificans isolates and for 31.6% of Scedosporium apiospermum isolates. Antagonism was not observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048969      PMCID: PMC1196235          DOI: 10.1128/AAC.49.8.3498-3500.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors:  Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.

Authors:  C Girmenia; G Luzi; M Monaco; P Martino
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Authors:  Thomas J Walsh; Irja Lutsar; Timothy Driscoll; Bertrand Dupont; Maureen Roden; Parvis Ghahramani; Michael Hodges; Andreas H Groll; John R Perfect
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

5.  Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans.

Authors:  Montserrat Ortoneda; Javier Capilla; Isabel Pujol; F Javier Pastor; Emilio Mayayo; Joan Fernández-Ballart; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

Review 6.  Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis.

Authors:  M A Nesky; E C McDougal; J E Peacock
Journal:  Clin Infect Dis       Date:  2000-09-27       Impact factor: 9.079

7.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  12 in total

1.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

2.  In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

Authors:  Carolina Serena; Marçal Mariné; Guillermo Quindós; Alfonso J Carrillo; J F Cano; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 3.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  Scedosporium apiospermum brain abscesses in an immunocompetent man with silicosis.

Authors:  Heather L Wilson; Karina J Kennedy
Journal:  Med Mycol Case Rep       Date:  2013-03-01

Review 5.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 6.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

7.  Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.

Authors:  M Mar Rodríguez; Enrique Calvo; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.

Authors:  Yongqin Wu; Nina Grossman; Marissa Totten; Warda Memon; Anna Fitzgerald; Chunmei Ying; Sean X Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Disseminated Scedosporium prolificans infection in a Labrador retriever with immune mediated haemolytic anaemia.

Authors:  Amanda Taylor; Jessica Talbot; Peter Bennett; Patricia Martin; Mariano Makara; Vanessa R Barrs
Journal:  Med Mycol Case Rep       Date:  2014-11-04

10.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.